Assessment and Effects of Circulating Cardiotonic Steroids in the RATE-AF Randomized Study Among Atrial Fibrillation and Heart Failure Patients - Scorecard - MDSpire
Advertisement
Assessment and Effects of Circulating Cardiotonic Steroids in the RATE-AF Randomized Study Among Atrial Fibrillation and Heart Failure Patients
Clinical Scorecard: Assessment and Effects of Circulating Cardiotonic Steroids in the RATE-AF Randomized Study Among Atrial Fibrillation and Heart Failure Patients
At a Glance
Category
Detail
Condition
Atrial Fibrillation and Heart Failure
Key Mechanisms
Inhibition of Na+/K+ ATPase, modulation of cardiac contractility and vascular tone.
Target Population
Patients aged 60 years or older with permanent atrial fibrillation requiring rate control and symptoms of NYHA class II or above.
Care Setting
Outpatient clinical trial setting.
Key Highlights
Low-dose digoxin is equivalent to beta-blockers for physical-related quality of life in AF patients.
Digoxin reduces HF-related death and hospitalisation compared to placebo.
Cardiotonic steroids may modulate digoxin's effects in patients with AF and HF.
Guideline-Based Recommendations
Diagnosis
Assess symptoms and classify using NYHA and mEHRA scores.
Management
Consider low-dose digoxin as a second-line therapy for rate control in AF patients with HF.
Monitoring & Follow-up
Monitor NT-proBNP levels and adverse events at follow-up visits.
Risks
Be aware of the narrow therapeutic range of digoxin and potential interactions with circulating cardiotonic steroids.
Patient & Prescribing Data
Patients with permanent atrial fibrillation and heart failure symptoms.
Digoxin may be preferable for patients intolerant to beta-blockers.
Clinical Best Practices
Use high-fidelity mass spectrometry for quantifying cardiotonic steroids in plasma.
Ensure informed consent for blood sample storage and processing.
by Ioannis Akoumianakis, Lorna C. Gilligan, Karina V. Bunting, Dannie Fobian, Paulus Kirchhof, Wiebke Arlt, Angela E. Taylor, Davor Pavlovic, Dipak Kotecha
